Park, Lauren K.
Lim, Kian-Huat
Volkman, Jonas
Abdiannia, Mina
Johnston, Hannah
Nigogosyan, Zack
Siegel, Marilyn J.
McGill, Janet B.
McKee, Alexis M.
Salam, Maamoun
Zhang, Rong M.
Ma, Da
Popuri, Karteek
Chow, Vincent Tze Yang
Beg, Mirza Faisal
Hawkins, William G.
Peterson, Linda R.
Ippolito, Joseph E.
Funding for this research was provided by:
National Institutes of Health (P50 CA196510, P30 CA91842, P50 CA196510, R21 HL145217, K99/R00 CA218869)
American Heart Association
Michael Smith Foundation for Health Research Innovation to Commercialization Program
Alvin J. Siteman Cancer Center
Foundation for Barnes-Jewish Hospital
Barnard Research Fund
Article History
Received: 17 January 2023
Accepted: 2 May 2023
First Online: 18 May 2023
Declarations
:
: This study was approved by the Washington University in St. Louis Institutional Review Board (HRPO#202011019) and registered as NCT04542291 on September 09, 2020. The study was conducted in accordance with the Declaration of Helsinki. All patients were prospectively consented to be in this trial.
: Not applicable.
: M.S. has research grants from Neurocrine Biosciences and Mylan and is a consultant for Eli Lilly and Neurocrine Biosciences.